Page 32 - Pfizer

Pfizer wins patent rights for autoimmune diseases' drug

The patent office dismissed the objections of two opponents and granted two process patents for Pfizer's etanercept

Pfizer profit just misses estimates; company scraps cholesterol drug

The drugmaker earned 61 cents per share in the third quarter, excluding special items, missing the average analyst estimate by 1 cent

Pfizer concludes Rs 110 crore deal with Piramal Enterprises

Pfizer shares on Monday ended at Rs 1,930.40 apiece on the BSE, down 1.66% from previous close

Pfizer to purchase antibiotics business of AstraZeneca

Deal could be valued at more than $1.5 billion

Pfizer to buy US cancer drug company Medivation for $14 billion

Pfizer, Merck, Celgene Corp and Gilead Sciences Inc had submitted expressions of interest to buy Medivation

Pfizer said close to $14-billion deal to acquire Medivation

The deal may be announced as early as Monday, said the people, who asked not to be identified because the matter is still private

Pfizer nears agreement to buy Medivation for $14 billion

Purchase would be Pfizer's biggest buy since it bought the medical device company Hospira last year for $17 billion

Pfizer to buy Anacor in $5.2-bn deal

The net-of-cash deal value assumes conversion of Anacor's outstanding convertible notes

Pfizer to acquire Anacor Pharmaceuticals for $5.2 bn

Anacor's flagship asset, crisaborole, is currently under review by the USFDA for the treatment of mild-to-moderate atopic dermatitis, commonly referred to as eczema

Pfizer restricts sale of its drugs used in executions

With this all 25 companies that produce medicines used in executions have blocked their sale for that purpose

Pfizer approaches Medivation about potential take-over

Medivation has not yet decided whether it should engage with Pfizer in negotiations and is in discussions with its financial and legal advisers

Pfizer needs Plan C after Allergan fallout

Pfizer's $152-billion merger with Allergan failed after the Obama administration introduced rules that would make the deal much less attractive

Pfizer to end its $160-bn Allergan deal

Move comes in as a major victory to US President Barack Obama's drive to stop tax-dodging corporate mergers

Obama's inversion curbs kill Pfizer's $160-bn Allergan deal

The decision by Obama administration to end the biggest tax 'inversion' ever attempted would otherwise have seen Pfizer slash its tax bill by redomiciling to Ireland where Allergan is registered

Pfizer, P&G stock down by up to 3% on drug ban

Pfizer stopped sale of cough syrups Corex and Phensedyl after govt banned over 300 fixed dose combination drugs

Delhi High Court grants Pfizer temporary relief on cough syrup ban

The court said the government had not issued Pfizer a 'show cause notice' before banning the medicine

Banning cough syrups will hit Pfizer most

Its brand Corex is a big contributor to revenues, but measure may reduce earnings estimate for firm

Delhi High Court grants interim; restrains sale of Corex syrup

Sale of over 300 drugs' combination have been banned; HC granted relief saying they've been in business for 25 years

Pfizer dips after ban on Corex cough syrup in India

The stock dipped 5% to Rs 1,827 on the BSE.

Pfizer stops selling popular Corex cough syrup in India after ban

India has banned over 344 drug combinations after a govt panel of experts found that they had no therapeutic justification